查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1943239

非治療性生物分子市場－全球產業規模、佔有率、趨勢、機會與預測：貿易藥品、終端用戶、地區和競爭格局，2021-2031年

Non-Therapeutic Biomolecules Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Trade Pharma, By End user (Research, Pharma, In vitro diagnostics, Others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球非治療性生物分子市場預計將從 2025 年的 286.3 億美元成長到 2031 年的 448.3 億美元，複合年成長率為 7.76%。

此市場領域涵蓋種類繁多的蛋白質、核酸和酶，主要用於體外診斷、工業生物加工和生命科學研究，但不直接用於病患治療。該行業的成長主要受臨床對高精度分子診斷日益成長的需求以及生產製造中永續「綠色化學」的日益普及所驅動，這標誌著工業生產正朝著生物基效率和先進檢測能力的方向發生根本性轉變。

市場概覽
預測期 2027-2031
市場規模：2025年 286.3億美元
市場規模：2031年 448.3億美元
複合年成長率：2026-2031年 7.76%
成長最快的細分市場 酵素
最大的市場 北美洲

然而，由於監管基因改造生物製劑安全性和核准的複雜法規結構，市場擴張面臨許多障礙。遵守這些嚴格的國際標準可能導致商業化進程顯著延遲，並增加製造商的研發成本。 MedTech Europe 的報告顯示，歐洲醫療技術市場規模預計到 2024 年將達到約 1,700 億歐元，這表明依賴這些生物分子的產業規模之大。

市場促進因素

早期疾病檢測的迫切需求推動了體外診斷 (IVD) 試劑盒和試劑需求的不斷成長，成為市場成長的主要催化劑。臨床檢查室高度依賴非治療性生物分子，例如單株抗體和聚合酵素，來進行感染疾病和腫瘤標記的精準檢測。這種持續的依賴也體現在主要製造商的財務表現中。羅氏於 2025 年 1 月發布的「2024 會計年度」報告預測，該公司診斷平台業務將成長 8%，凸顯了全球檢測所需的大量生物材料。此外，在整個生命科學領域，基因組研究和藥物研發的大規模資本投資持續推動試劑消耗。賽默飛世爾科技對 2024 會計年度全年營收的預測為 428.8 億美元，這表明支持這些研究活動的龐大基礎設施規模。

隨著各行業向生物基效率轉型，酵素在工業製造過程中的應用日益廣泛，也推動了市場的發展。從生質能源到家用產品，催化蛋白正逐漸被合成化學物質所取代，以降低能源消耗和環境影響。這就需要持續、大規模地供應專為在嚴苛加工環境中保持穩定性而設計的專用酵素。領先的生物解決方案供應商的表現顯示了這項轉型的商業性可行性。根據Novonesys公司於2025年2月發布的2024年度報告，該公司旗下行星健康生物解決方案部門的有機銷售額按備考基準計算成長了9%。這一成長軌跡凸顯了該產業對生物催化劑的日益依賴，以實現永續性目標和更環保的生產方法監管標準。

市場挑戰

複雜的法規結構，包括對基因改造生物製劑的核准和安全監管，對全球非治療性生物分子市場的擴張構成了重大障礙。該領域的製造商，特別是那些開發用於工業生物加工的酶和用於診斷應用的試劑的製造商，面臨著嚴格的合規要求，而這些要求在不同司法管轄區之間差異顯著。這些嚴格的標準迫使企業投入大量資源用於法律檢驗和安全資料生成，阻礙了資本向產能和創新領域的配置。由此產生的漫長核准流程造成了嚴重的瓶頸，延緩了先進生物基解決方案的市場准入，並削弱了那些尋求將永續產品商業化以替代傳統化學產品的製造商的競爭優勢。

這些監管壁壘對產業的影響顯著且深遠，造成的差異直接阻礙了市場效率。 2024 年 EuropaBio 的報告顯示，生物防治產品（利用工業生物分子的關鍵領域）在歐洲獲得市場核准的平均時間為 7-8 年，而其他地區僅需 2-3 年。這些顯著的延誤不僅增加了開發商的財務風險，也阻礙了本地投資，儘管生物基工業工具的潛在需求龐大，但實際上卻阻礙了該產業的發展。

市場趨勢

胜肽和蛋白質在化妝品領域的應用不斷擴展，正逐步將市場焦點從臨床診斷和工業流程轉移開來。護膚品擴大添加生物活性蛋白和合成胜肽，以提供以往僅限於皮膚治療的功能性益處，模糊了化妝品和藥品之間的界限。這一趨勢的特點是，專門針對皮膚修復的訊號肽和生長因子實現了商業化，為專業原料供應商創造了可觀的收入來源。這一高附加價值細分市場的商業性影響十分顯著。根據歐萊雅於2025年2月發布的2024年財務報告，其皮膚科化妝品部門實現了9.8%的年成長，銷售額累計70億歐元。這顯示消費者對經科學驗證、富含生物分子的護膚產品的需求正在加速成長。

同時，人工智慧在加速生物分子發現的應用正在革新非治療性藥物的開發平臺。透過利用生成模型和機器學習，研究人員可以繞過傳統高通量篩檢中重複的瓶頸環節，以前所未有的速度預測蛋白質結構和酵素功能。這種技術融合使得針對特定工業和消費應用進行最佳化的新型酵素的精確設計成為可能，從而顯著縮短產品上市時間和降低研發成本。為了進一步反映對計算生物學的依賴，Ginkgo Bioworks 在 2024 年 11 月的 2024 會計年度第三季財報電話會議上宣布，其細胞工程平台新增了 25 個項目，這標誌著業界正持續向數據驅動的生物探勘轉型，以解決複雜的生物工程難題。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球非治療性生物分子市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥品（酵素、重組蛋白、質體、胜肽、寡核苷酸、單株抗體）
    • 依最終用戶（研究、製藥、體外診斷（IVD）、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美非治療性生物分子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲非治療性生物分子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區非治療性生物分子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲非治療性生物分子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲非治療性生物分子市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球非治療性生物分子市場：SWOT 分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck Group.
  • Bio-Synthesis Inc.
  • Eurogentec
  • Aviva Systems Biology
  • RayBiotech
  • Biocon Limited
  • Bio-Techne Corporation
  • Danaher Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19521

The Global Non-Therapeutic Biomolecules Market is projected to expand from a valuation of USD 28.63 Billion in 2025 to USD 44.83 Billion by 2031, registering a CAGR of 7.76%. This market sector comprises a diverse array of proteins, nucleic acids, and enzymes utilized principally for in vitro diagnostics, industrial bio-processing, and life science research, rather than for direct patient therapy. The growth of this industry is fundamentally driven by the rising necessity for high-precision molecular diagnostics within clinical settings and the increasing adoption of sustainable "green chemistry" in manufacturing, representing a structural shift toward bio-based industrial efficiency and advanced testing capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 28.63 Billion
Market Size 2031USD 44.83 Billion
CAGR 2026-20317.76%
Fastest Growing SegmentEnzymes
Largest MarketNorth America

However, market expansion encounters significant obstacles regarding the complex regulatory frameworks that govern the safety and approval of genetically modified biological agents. Compliance with these rigorous international standards can lead to substantial delays in commercialization and escalated development costs for manufacturers. Highlighting the magnitude of the industries dependent on these biomolecules, MedTech Europe reported that the European medical technology market was estimated to be approximately €170 billion in 2024.

Market Driver

The rising demand for In Vitro Diagnostic (IVD) kits and reagents acts as a primary catalyst for market growth, driven by the critical need for early disease detection. Clinical laboratories rely heavily on non-therapeutic biomolecules, such as monoclonal antibodies and polymerase enzymes, to execute sensitive assays for infectious diseases and oncological markers. This enduring reliance is reflected in the financial performance of major manufacturers; according to Roche's 'Full Year 2024 Results' released in January 2025, the company's diagnostics base business grew by 8 percent, underscoring the substantial volume of biological materials required for global testing. Additionally, the broader life sciences sector continues to fuel reagent consumption through massive capital allocation toward genomic research and drug discovery, with Thermo Fisher Scientific reporting full-year 2024 revenue of $42.88 billion in 2025, demonstrating the immense scale of the infrastructure supporting these research activities.

The expanding application of enzymes in industrial manufacturing processes concurrently propels the market as industries transition toward bio-based efficiency. Sectors ranging from bioenergy to household care are substituting synthetic chemicals with catalytic proteins to lower energy consumption and reduce environmental impact, necessitating a consistent industrial-scale supply of specialized enzymes engineered for stability in harsh processing environments. The commercial viability of this transition is evident in the performance of leading biosolution providers; according to Novonesis' 'Annual Report 2024' published in February 2025, the company's Planetary Health Biosolutions segment achieved pro forma organic sales growth of 9 percent. This trajectory highlights the rising industrial dependency on biological catalysts to meet sustainability targets and regulatory standards for greener production methods.

Market Challenge

The intricate regulatory frameworks governing the approval and safety of genetically modified biological agents constitute a substantial impediment to the expansion of the Global Non-Therapeutic Biomolecules Market. Manufacturers in this sector, particularly those developing enzymes for industrial bioprocessing and reagents for diagnostic applications, face increasingly rigorous compliance requirements that vary significantly across jurisdictions. These stringent standards force companies to allocate extensive resources toward legal validation and safety data generation, diverting capital away from production capacity and innovation. Consequently, the prolonged approval timelines create severe bottlenecks, delaying the entry of advanced bio-based solutions into the market and eroding the competitive advantage of manufacturers attempting to commercialize sustainable alternatives to traditional chemical products.

The impact of these regulatory hurdles is quantifiable and severe within the industry, creating a disparity that directly hampers market efficiency. According to EuropaBio in 2024, the average time required to obtain market authorization for biocontrol products-a key segment utilizing industrial biomolecules-was between seven and eight years in Europe, compared to just two to three years in other global regions. This extensive delay not only increases financial risk for developers but also disincentivizes regional investment, effectively stalling the sector's momentum despite the underlying demand for bio-based industrial tools.

Market Trends

The expansion of peptide and protein applications in cosmeceuticals is steadily shifting market focus beyond clinical diagnostics and industrial processing. Personal care formulations are increasingly incorporating bioactive proteins and synthetic peptides to deliver functional benefits previously reserved for dermatological therapies, effectively blurring the line between cosmetics and pharmaceuticals. This trend is characterized by the commercialization of signal peptides and growth factors tailored for skin repair, driving substantial revenue streams for specialized ingredient suppliers. The commercial impact of this high-value segment is robust; according to L'Oreal's '2024 Annual Results' in February 2025, the company's Dermatological Beauty Division achieved like-for-like growth of 9.8 percent, generating sales of €7 billion, which highlights the accelerating consumer appetite for scientifically validated, biomolecule-enriched skincare products.

Simultaneously, the integration of Artificial Intelligence for accelerated biomolecule discovery is revolutionizing the development pipeline for non-therapeutic agents. By leveraging generative models and machine learning, researchers can now predict protein structures and enzymatic functions with unprecedented speed, bypassing the iterative bottlenecks of traditional high-throughput screening. This technological convergence allows for the precise engineering of novel enzymes optimized for specific industrial or consumer applications, significantly reducing time-to-market and development costs. Validating this increasing reliance on computational biology, Ginkgo Bioworks reported in its 'Q3 2024 Financial Results' in November 2024 that the company added 25 new programs to its Cell Engineering platform, signaling a persistent industry shift toward data-driven bioprospecting to solve complex biological engineering challenges.

Key Market Players

  • Merck Group.
  • Bio-Synthesis Inc.
  • Eurogentec
  • Aviva Systems Biology
  • RayBiotech
  • Biocon Limited
  • Bio-Techne Corporation
  • Danaher Corporation

Report Scope

In this report, the Global Non-Therapeutic Biomolecules Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Therapeutic Biomolecules Market, By Trade Pharma

  • Enzymes
  • Recombinant Proteins
  • Plasmids
  • Peptides
  • Oligonucleotides
  • Monoclonal Antibodies

Non-Therapeutic Biomolecules Market, By End user

  • Research
  • Pharma
  • In vitro diagnostics(IVD)
  • Others

Non-Therapeutic Biomolecules Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Therapeutic Biomolecules Market.

Available Customizations:

Global Non-Therapeutic Biomolecules Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Therapeutic Biomolecules Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Trade Pharma (Enzymes, Recombinant Proteins, Plasmids, Peptides, Oligonucleotides, Monoclonal Antibodies)
    • 5.2.2. By End user (Research, Pharma, In vitro diagnostics(IVD), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Non-Therapeutic Biomolecules Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Trade Pharma
    • 6.2.2. By End user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Therapeutic Biomolecules Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Trade Pharma
        • 6.3.1.2.2. By End user
    • 6.3.2. Canada Non-Therapeutic Biomolecules Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Trade Pharma
        • 6.3.2.2.2. By End user
    • 6.3.3. Mexico Non-Therapeutic Biomolecules Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Trade Pharma
        • 6.3.3.2.2. By End user

7. Europe Non-Therapeutic Biomolecules Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Trade Pharma
    • 7.2.2. By End user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Therapeutic Biomolecules Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Trade Pharma
        • 7.3.1.2.2. By End user
    • 7.3.2. France Non-Therapeutic Biomolecules Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Trade Pharma
        • 7.3.2.2.2. By End user
    • 7.3.3. United Kingdom Non-Therapeutic Biomolecules Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Trade Pharma
        • 7.3.3.2.2. By End user
    • 7.3.4. Italy Non-Therapeutic Biomolecules Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Trade Pharma
        • 7.3.4.2.2. By End user
    • 7.3.5. Spain Non-Therapeutic Biomolecules Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Trade Pharma
        • 7.3.5.2.2. By End user

8. Asia Pacific Non-Therapeutic Biomolecules Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Trade Pharma
    • 8.2.2. By End user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Therapeutic Biomolecules Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Trade Pharma
        • 8.3.1.2.2. By End user
    • 8.3.2. India Non-Therapeutic Biomolecules Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Trade Pharma
        • 8.3.2.2.2. By End user
    • 8.3.3. Japan Non-Therapeutic Biomolecules Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Trade Pharma
        • 8.3.3.2.2. By End user
    • 8.3.4. South Korea Non-Therapeutic Biomolecules Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Trade Pharma
        • 8.3.4.2.2. By End user
    • 8.3.5. Australia Non-Therapeutic Biomolecules Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Trade Pharma
        • 8.3.5.2.2. By End user

9. Middle East & Africa Non-Therapeutic Biomolecules Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Trade Pharma
    • 9.2.2. By End user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Therapeutic Biomolecules Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Trade Pharma
        • 9.3.1.2.2. By End user
    • 9.3.2. UAE Non-Therapeutic Biomolecules Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Trade Pharma
        • 9.3.2.2.2. By End user
    • 9.3.3. South Africa Non-Therapeutic Biomolecules Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Trade Pharma
        • 9.3.3.2.2. By End user

10. South America Non-Therapeutic Biomolecules Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Trade Pharma
    • 10.2.2. By End user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Therapeutic Biomolecules Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Trade Pharma
        • 10.3.1.2.2. By End user
    • 10.3.2. Colombia Non-Therapeutic Biomolecules Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Trade Pharma
        • 10.3.2.2.2. By End user
    • 10.3.3. Argentina Non-Therapeutic Biomolecules Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Trade Pharma
        • 10.3.3.2.2. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Therapeutic Biomolecules Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck Group.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Synthesis Inc.
  • 15.3. Eurogentec
  • 15.4. Aviva Systems Biology
  • 15.5. RayBiotech
  • 15.6. Biocon Limited
  • 15.7. Bio-Techne Corporation
  • 15.8. Danaher Corporation

16. Strategic Recommendations

17. About Us & Disclaimer